

Ref. No.: LASA/SE/25-26/35

Friday September 05, 2025

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
--	--

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held today i.e. September 05, 2025**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Board of Directors at their meeting held today which commenced at 07.00 pm and concluded at 8.00 pm have considered and approved the following:

- 1) The Notice of the Tenth (10<sup>th</sup>) Annual general Meeting (AGM) of the Company
- 2) The 10<sup>th</sup> AGM is scheduled to be held on Tuesday, September 30, 2025 at 11.00 A.M. through Video conferencing (VC) / Other Audio-Visual means (OAVM).
- 3) The Director’s Report of the Company together with Report on Corporate Governance, Management Discussion and Analysis Report and other relevant annexures & Schedules thereto for the financial year ended March 31, 2025.
- 4) Appointment of Shravan A. Gupta & Associates, Practicing Company Secretaries as a scrutinizer for 10<sup>th</sup> Annual General Meeting.
- 5) Re-Appointment of Mr. Omkar Herlekar (DIN: 01587154), Director who is liable to retire by rotation and eligible for re-appointment.
- 6) To close Register of Members and Share Transfer Books of the Company from Tuesday 23<sup>rd</sup> September 2025 to Monday 29<sup>th</sup> September 2025 both days inclusive.



The above information is also available on the company's website at [www.lasalabs.com](http://www.lasalabs.com) and on the website of the stock Exchange at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

**FOR LASA SUPERGENERICS LIMITED**

**OMKAR HERLEKAR**  
**CHAIRMAN AND MANAGING DIRECTOR**  
**DIN: 01587154**

A large, light blue watermark of the LASA logo is centered on the page. It consists of the word "LASA" in a large, bold, sans-serif font, with a red swoosh underline that extends from the left and curves under the letters. A red dot is positioned at the end of the swoosh on the right side.

**AS REQUIRED UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 DETAILS OF RE-APPOINTMENT OF THE AFORESAID DIRECTORS ARE ENCLOSED AS AN ANNEXURE.**

<b>Name of Director</b>	Dr. Omkar Pravin Herlekar
<b>Director Identification No.</b>	01587154
<b>Date of Birth</b>	March 13,1981
<b>Date of appointment on Board</b>	May 02, 2017
<b>Nationality</b>	Indian
<b>Qualifications</b>	Doctorate in Philosophy (Science) from the Institute of Chemical Technology, Mumbai and a degree of Masters of Science (By Research) (Theory) from University of Mumbai
<b>Expertise in specific functional areas</b>	<p>Dr. Omkar P. Herlekar is the Chairman and Managing Director of Lasa Supergenerics Limited. Upon assuming the leadership of Lasa, Dr. Herlekar charted a multi-pronged approach for its corporate growth. Envisioning a global presence for the group, Dr. Herlekar played a pivotal role in establishing marketing set-up across and outside India. Lasa places immense focus on research. Dr. Herlekar has played a pivotal role in embryonic the group's 'Catalyst Chemistry' division that focuses on development of veterinary APIs and breakthrough innovations. His contributions are widely acclaimed in the industry circles. Under his leadership, Lasa achieved new milestones and offered several innovations with the help of 'backward integration'. Herlekar's visionary and astute entrepreneurial leadership resulted in Lasa emerging as one of the leading animal healthcare conglomerates in India, driven by research, and strategic thinking on a global scale. His clear vision, steady guidance and boundless passion for organic chemistry serve as catalysts for the steady and continued expansion of the group.</p> <p>He also holds number of 'process patents' to his credit. Dr. Herlekar spearheads business development, expansion initiatives, financial management,</p>

	investment and regulatory affairs. He has a team of experienced technocrats who are dedicated towards scaling the group to greater heights through innovation and excellence, thereby creating value for its stakeholders.
<b>List of Directorships held in Other Companies (Excluding Foreign, Private and Section 8 Companies)</b>	Nil
<b>Memberships/ Chairmanships of Audit and Stakeholders' Relationships Committees across Public Companies</b>	Membership – 2 (Two):- in Audit Committee and Stakeholders' Relationship Committee of Lasa Supergenerics Limited Member in Audit Committee
<b>Number of shares held in the Company</b>	26879661*
<b>Relationships between the Directors inter-se</b>	N.A

**FOR LASA SUPERGENERICS LIMITED**

**OMKAR HERLEKAR**  
**CHAIRMAN AND MANAGING DIRECTOR**  
**DIN: 01587154**